Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Erin B. Yoder"'
Autor:
Mehran Habibi, Danijela Jelovac, Rima Couzi, Cesar Augusto Santa-Maria, Catherine Klein, Marissa White, Nivali Naik, Jennifer Wei, Yen Huynh, Architha Ellappalayam, Lisa E. Blumencranz, Erin B. Yoder, Patricia Dauer, Bas van der Baan, William Audeh
Publikováno v:
Cancer Research. 83:P5-09
BACKGROUND: Neoadjuvant Endocrine Therapy (NET) is seldom used in breast cancer management except in patients with several comorbidities or in elderly patients in which chemotherapy is not an option. Clinical response with NET is not typically achiev
Autor:
Pat W. Whitworth, Peter D. Beitsch, Mary K. Murray, Paul D. Richards, Angela Mislowsky, Carrie L. Dul, James V. Pellicane, Paul L. Baron, Rakhshanda Layeequr Rahman, Laura A. Lee, Beth B. Dupree, Pond R. Kelemen, Andrew Y. Ashikari, Raye J. Budway, Cristina Lopez-Penalver, William Dooley, Shiyu Wang, Patricia Dauer, Andrea R. Menicucci, Erin B. Yoder, Christine Finn, Lisa E. Blumencranz, William Audeh
Publikováno v:
JCO precision oncology. 6
PURPOSE The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete respons
Autor:
James V. Pellicane, Peter D. Beitsch, David T. Rock, Raye J. Budway, Carrie L. Dul, Pond R. Kelemen, Andrew Y. Ashikari, Paul L. Baron, Paul D. Weinstein, Angela Mislowsky, Laura A. Lee, Jennifer Beatty, Mary K. Murray, Beth B. Dupree, Christine Finn, Kate Corcoran, Shiyu Wang, Andrea R. Menicucci, Erin B. Yoder, Lisa E. Blumencranz, Patricia Dauer, William Audeh, Pat W. Whitworth
Publikováno v:
Surgical oncology. 45
As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are likely to benefit from NET. NBRST (NCT01479101) compared the
Autor:
Adam M. Brufsky, Midas Kuilman, Rita Mukhtar, Denise M. Wolf, Christina Yau, Joyce O’Shaughnessy, Cathy Graham, Vijayakrishna K. Gadi, Pat Whitworth, Alexander Hindenburg, Ian Grady, Gordon Srkalovic, Kent Hoskins, Ajay Dhakal, Cynthia Ma, Natasha Hunter, Jennifer Crozier, Blanche Mavromatis, Lorenza Mittempergher, Christine Finn, Shraddha Modh, Erin B. Yoder, Patricia Dauer, Andrea Menicucci, Bas van der Baan, William Audeh, Laura J. Esserman
Publikováno v:
Cancer Research. 83:PD9-08
BACKGROUND: Immune checkpoint inhibitors in combination with chemotherapy have demonstrated an improvement of pathologic complete response (pCR) in patients with HR-HER2- and MammaPrint (MP) High Risk, HR+HER2- tumors in the I-SPY2 TRIAL. However, no
Autor:
Pat W, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Mary K, Murray, Mark A, Gittleman, Raye J, Budway, Rakhshanda Layeequr, Rahman, Pond R, Kelemen, William C, Dooley, David T, Rock, Kenneth H, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth B, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
JCO Precision Oncology.
PURPOSE The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Ba
Autor:
Pat, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Charles H, Nash, Mary K, Murray, Paul D, Richards, Mark, Gittleman, Raye, Budway, Rakhshanda Layeequr, Rahman, Pond, Kelemen, William C, Dooley, David T, Rock, Ken, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
Annals of surgical oncology.
The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)